Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BEZ235 + Abiraterone in mCRPC
NCT01717898Phase 2Terminated
- Start
- Jan 2013
- Primary completion
- Sep 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of dactolisib in metastatic castration-resistant prostate cancer (mCRPC). Started Jan 2013; status: terminated.
02
Drugs
dactolisib
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT01717898.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01717898.